Lindbrook Capital, LLC - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 238 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2021. The put-call ratio across all filers is 1.29 and the average weighting 0.1%.

Quarter-by-quarter ownership
Lindbrook Capital, LLC ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$3,030
-70.1%
85
-61.4%
0.00%
-100.0%
Q2 2023$10,149
+31.8%
220
+14.6%
0.00%0.0%
Q1 2023$7,699
-62.2%
192
-56.4%
0.00%
-66.7%
Q4 2022$20,385
+307.7%
440
+286.0%
0.00%
+200.0%
Q3 2022$5,000
+150.0%
114
+307.1%
0.00%
Q1 2022$2,0000.0%28
+16.7%
0.00%
Q4 2021$2,000
+100.0%
24
+242.9%
0.00%
Q1 2021$1,0000.0%7
-58.8%
0.00%
Q4 2019$1,000
-75.0%
17
-80.5%
0.00%
-100.0%
Q3 2019$4,0000.0%87
+38.1%
0.00%0.0%
Q2 2019$4,0000.0%630.0%0.00%0.0%
Q1 2019$4,000
+100.0%
630.0%0.00%
+100.0%
Q4 2018$2,000630.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q2 2021
NameSharesValueWeighting ↓
First Light Asset Management, LLC 437,512$31,772,0002.80%
RTW INVESTMENTS, LP 1,373,284$99,728,0002.06%
Rock Springs Capital Management LP 1,028,109$74,661,0001.88%
Privium Fund Management B.V. 112,727$8,186,0001.81%
Avidity Partners Management LP 869,000$63,107,0001.31%
SUVRETTA CAPITAL MANAGEMENT, LLC 525,100$38,133,0001.16%
Boxer Capital, LLC 200,000$14,524,0000.75%
SECTOR GAMMA AS 46,221$3,357,0000.73%
FEDERATED HERMES, INC. 3,987,728$289,589,0000.65%
EMERALD ADVISERS, LLC 223,952$16,263,0000.62%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders